scPharmaceuticals options converted to cash and CVRs in MannKind merger
Rhea-AI Filing Summary
scPharmaceuticals Inc. (SCPH) reported that on 10/07/2025 a reporting person canceled a set of stock options in connection with a completed tender offer under an Agreement and Plan of Merger with MannKind Corporation. A series of Company Options with exercise prices below $5.35 were cancelled and converted into a cash payment equal to the per‑share spread between $5.35 and each option's exercise price, and into one contingent value right (CVR) per underlying share.
The Form 4 lists five option grants totaling 84,422 underlying shares canceled: strikes of $3.85, $4.11, $4.53, $3.37, and $4.80, with varying expiration dates between 06/18/2029 and 06/03/2035. The filing is administrative evidence of the merger consideration mechanics for option holders: immediate cash for intrinsic value and CVRs for additional contingent consideration.
Positive
- Option holders received cash equal to the per‑share spread versus $5.35, providing immediate value
- Each canceled option also converts into one CVR, offering contingent upside beyond the cash spread
- Total option overhang reduced by cancellation of 84,422 underlying shares, simplifying the post‑transaction cap table
Negative
- Unexercised options were cancelled, eliminating potential future upside from stock appreciation for holders of those awards
- Cash paid equals only the intrinsic spread, so holders with meaningful upside above $5.35 (if any) receive no participation beyond CVRs
- CVR value and payout terms are not detailed here, creating uncertainty about the ultimate compensation for former option holders
Insights
Option cancellations reflect standard merger consideration and alignment of outstanding equity with transaction terms.
The Merger Agreement converts Company Options with exercise prices under $5.35 into cash equal to the spread and one CVR per share, which removes outstanding option overhang and simplifies the post‑closing cap table.
This reduces administrative complexity for the combined company but removes future upside for option holders; monitor CVR terms and any payout milestones over the post‑closing period for concrete value realization.
84,422 option shares were canceled on 10/07/2025, with cash and CVR consideration replacing unexercised awards.
The filing lists five option grants (strikes from $3.37 to $4.80) totaling 84,422 shares; each cancelled option yields a cash payment equal to ($5.35 minus exercise price) times shares, and one CVR per share.
Key items to watch are the CVR structure and timing to assess residual value, and whether any remaining options had exercise prices at or above $5.35 (unchanged by this provision).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 19,750 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 16,300 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 6,124 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 12,248 | $0.00 | -- |
Footnotes (1)
- In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
